ImmuneOnco Biopharmaceuticals (Shanghai) Full Year 2024 Earnings: CN¥0.84 loss per share (vs CN¥1.05 loss in FY 2023)
ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Full Year 2024 ResultsKey Financial Results Revenue: CN¥79.5m (up by CN¥71.8m from FY 2023). Net loss: CN¥315.9m (loss narrowed by...
Graham Says He Has Broad Senate Support for New Russia Sanctions
A key US Senate ally of President Donald Trump said he has the commitment of 72 colleagues for a bill that would enact “bone-crushing”...
Bloomberg Intelligence boosts Solana ETF approval odds to 90%
Bloomberg Intelligence has boosted its estimated odds of US regulators approving a Solana exchange-traded fund (ETF) in 2025 to 90%, according to an April...
US lawmakers ask Rubio for answers on Chinese fighters in Ukraine
U.S. lawmakers have asked the State Department to brief them about Russia's use of Chinese fighters in its war in Ukraine, saying in a...
Explosion in residential area in China's Shanxi kills at least one, state media reports
At least one person was killed and 21 others injured when an explosion rocked a residential area in northern China's Shanxi province, creating clouds...
